Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
Data Collection on Adverse Events of Anti-HIV Drugs Study Group; Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD. Data Collection on Adverse Events of Anti-HIV Drugs Study Group, et al. Clin Infect Dis. 2008 Apr 1;46(7):1101-10. doi: 10.1086/528862. Clin Infect Dis. 2008. PMID: 18461712 Free PMC article.
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, Menichetti F, Mastroianni CM, Tumbarello M, Grossi P, Artioli S, Carannante N, Cipriani L, Coletto D, Russo A, Digaetano M, Losito AR, Peghin M, Capone A, Nicolè S, Vena A; CEFTABUSE Study Group. Bassetti M, et al. Int J Antimicrob Agents. 2019 Apr;53(4):408-415. doi: 10.1016/j.ijantimicag.2018.11.001. Epub 2018 Nov 8. Int J Antimicrob Agents. 2019. PMID: 30415002 Free article.
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study).
Bassetti M, Vena A, Giacobbe DR, Falcone M, Tiseo G, Giannella M, Pascale R, Meschiari M, Digaetano M, Oliva A, Rovelli C, Carannante N, Losito AR, Carbonara S, Mariani MF, Mastroianni A, Angarano G, Tumbarello M, Tascini C, Grossi P, Mastroianni CM, Mussini C, Viale P, Menichetti F, Viscoli C, Russo A; CEFTABUSE Study Group. Bassetti M, et al. Open Forum Infect Dis. 2020 Apr 21;7(5):ofaa139. doi: 10.1093/ofid/ofaa139. eCollection 2020 May. Open Forum Infect Dis. 2020. PMID: 32462046 Free PMC article.
Approach to patients with COVID-19 disease: the procedure in Udine.
Agostinis P, Bontempo G, Della Siega P, Gerussi V, Pagotto A, Barbano E, Mazzoran L, Calci M, Sponza M, Sbrana F, Fapranzi S, Baritussio A, Tascini C. Agostinis P, et al. Among authors: bontempo g. New Microbiol. 2021 Jan;44(1):66-69. Epub 2020 Dec 16. New Microbiol. 2021. PMID: 33453703 Free article. Clinical Trial.
Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19.
Peghin M, Bouza E, Fabris M, De Martino M, Palese A, Bontempo G, Graziano E, Gerussi V, Bressan V, Sartor A, Isola M, Tascini C, Curcio F. Peghin M, et al. Among authors: bontempo g. Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2597-2604. doi: 10.1007/s10096-021-04335-x. Epub 2021 Aug 11. Eur J Clin Microbiol Infect Dis. 2021. PMID: 34378086 Free PMC article.
29 results